Skip directly to content

Press contact in New York:
Bryn Gay, +1 954 482 1421
HCV Project Director, Treatment Action Group
bryn.gay@treatmentactiongroup.org


Advocates scandalized that Gilead’s hepatitis C profit have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billion in profits.

6 December 2018, Paris, France, New York, NY— People living with hepatitis C, access to medicines activists, and the medical community around the world “mark” the fifth birthday of the first all-oral, one dose per day cure sofosbuvir (Sovaldi®), launched by Gilead Sciences.

tag_update_pg_1_400x505_2.jpg

I want to thank you all of you for the support that enabled the successes TAG achieved this past year. Despite a challenging political climate and continued attacks against those living with or at risk of contracting HIV, tuberculosis (TB), or hepatitis C virus (HCV), we’ve made significant progress.

As you'll see In TAG Update, in 2018 TAG’s HIV program expanded our Ending the Epidemic work within New York State and nationally.

Download the full report as a PDF
Download the slide deck JPGs

tb_rd_2018_cover_291x428.pngDecember 3, 2018 – Global funding for tuberculosis (TB) research climbed to a previously unreported high of USD $772 million in 2017, according to a report released today by Treatment Action Group (TAG) and the United Nations-hosted Stop TB Partnership. This marks the second year in a row that funding for TB research and development (R&D) exceeded $700 million.

Earlier this year, TAG released preliminary data on TB R&D funding in 2017 in advance of the first-ever United Nations High-Level Meeting on TB, held during the UN General

New York, November 26, 2018 – Treatment Action Group (TAG) decries the claimed use of CRISPR technology to edit genes for the HIV co-receptor CCR5 in human embryos for implantation.

Yesterday, He Jiankui, an Associate Professor at the South University of Science and Technology of China, posted a video to YouTube claiming to have employed CRISPR/Cas9 technology to edit the genetic code of embryos, leading to the birth of twins with mutated genes for the HIV co-receptor CCR5.1  The announcement has triggered extensive media coverage and ignited a firestorm of controversy.

“Treatment Action

DOWNLOAD TAG'S COMMENT (below as text)

Comment on The Food and Drug Administration (FDA) Notice: Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank; Draft Guidance for Food and Drug Administration Staff, Responsible Parties, and Submitters of Certain Applications and Submissions to the Food and Drug Administration

Treatment Action Group (TAG) fully supports the proposed guidance regarding civil money penalties relating to the clinicaltrials.gov data bank.

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for

November 16, 2018

About the position
Treatment Action Group (TAG) is seeking a highly motivated and organized Director of Finance and Operations to manage and help execute its operations, with a strong focus on building systems for more efficient work and communication within and across the organization. This position will report to the Executive Director, and be based in New York City.

The Director of Finance and Operations will supervise TAG’s Finance Manager and Administrator.

DOWNLOAD the report

TAG welcomes feedback on this report and the recommendations – please send any comments to: richard.jefferys@treatmentactiongroup.org

Introductory Summary

rj_comm_recs_cover_288x360.png

  • Combination antiretroviral therapy (ART) is now recommended for all people with HIV. Suppression of HIV viral load to undetectable levels by ART greatly benefits individual health—causing lifespans for many people with HIV to approach those of comparable HIV-negative individuals—and eliminates the risk of most forms of HIV transmission.
  • Scientists working to develop a cure for HIV infection sometimes need to conduct

READ THE LETTER

The immense worldwide investment of the Global Fund to Fight AIDS, TB and Malaria (GFATM) has proven effective to ensure increased access to an affordable, high-quality, and sustained supply of TB drugs. In order to support countries to transition from GFATM funding and towards national financing and procurement of TB, HIV, and malaria drugs, GFATM has instituted a Sustainability, Transition and Co-Financing (STC) policy.

Research Toward a Cure Trials Supplemental References Page

Treatment Intensification/Early Treatment

AAHIV/RV254: Antiretroviral therapy for acute HIV infection
NCT00796263

Establish and characterize an acute HIV infection cohort in a high-risk population
NCT00796146 (related observational study)

References

Kroon E, Pham PT, Sirivichayakul S, et al. Transmission dynamics among participants initiating antiretroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand. AIDS. 2018 Oct 23;32(16):2373-2381. doi: 10.1097/QAD.0000000000001956. 

Chintanaphol M, Sacdalan C, Chottanapund S, et al. Brief Report: Safety and Tolerability of

cap_jab_logos_final858x334.png

In a symbolic display, activists invited conference participants to discard the injectable agents and commit to rapidly scaling up access to safer, more effective medicines

Press contact in The Hague: Lindsay McKenna, +1 631 258 0808, Lindsay.McKenna@treatmentactiongroup.org, English

Press contact in New York: Erica Lessem, +1 212 253 7922, Erica.Lessem@treatmentactiongroup.org, English & Spanish

DOWNLOAD this release as a PDF

The Hague, Netherlands – October 25, 2018 – Activists from around the world called on National TB Programs to discontinue routine use of harmful injectable agents in

Pages